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Abstract
Diabetes therapy has dramatically progressed, but the chronic complications such as microvascular and macrovascular
complications are still the important causes of morbidity and mortality rates in diabetic patients. Metabolic perturbations such as oxidative
stress, advance glycation end product formation, protein kinase C and NFκB activation, increased polyol flux, and poly(ADP-ribose)
polymerase-1 (PARP-1) activation play key roles in the onset of the chronic complications. However, the direct cause is not discovered. Thus,
the treatments for the purpose to cure the complications are not established. Recently, we found bone marrow-derived cells that have
abnormal characteristics in their stem cell phase, and were related to the onset of the diabetic complications. Here we show some evidences
that the abnormal bone marrow-derived cells were formed under the high-glucose toxic condition in the bone marrow stem cells, which was
produced by diabetic hyperglycemia, and played a major role as an important pathogenesis of the chronic complications in diabetes mellitus.
Based on those results, we will describe some strategies that lead to the development of new treatments against their evil characteristics of
the diabetic bone marrow stem cells.
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リボース ) ポリメラーゼ -1 (PARP-1) などが報告され
てきた。確かにこれらの変化は高血糖状態に伴う代謝
異常が原因として起こってくるものである (図 1) [1]。































































































































































制 御 に 関 わ る 細 胞 と し て カ ハ ー ル の 間 質 細 胞





ICC は特異的なマーカーとして c-KIT の染色が用いら
れている。実際、糖尿病患者では大腸における c-KIT
陽性細胞の数を調べて、 ICC の数の減少が報告されて







（２） GFP 陽性細胞は c-Kit が陽性のものとそうでな
いものがあるが、糖尿病では c-Kit 陽性細胞の
































































TNFαに接着し、細胞内の reverse signaling を介して
DRG 内で発現している TNFα -mRNA の発現を抑制し
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